A Phase 3 interventional study of Rifaximin and Placebo in Diarrhea, sponsored by Bausch Health Americas, Inc.. Completed at 1 site in Mexico. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-18.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rifaximin in Diarrhea — 1 open to participants now, 2 under way, none of them phase 3. Rifaximin · Diarrhea.
Among the 19 studies testing rifaximin in Diarrhea, this one is the 10th largest by enrollment, is one of 3 that started in 2005, is one of 10 in phase 3, and was the 8th registered.
879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.
Browse Diarrhea studies →1 of the 19 studies testing rifaximin in Diarrhea is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
By country, each count listing its studies:
Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2005.
This study's enrollment of 210 is above the median of 138 across 739 interventional studies indexed under Diarrhea.
Median enrollment 210 across the 19 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
11 studies in Diarrhea by Bausch Health Companies Inc.: 1 open now, 1 under way, none of them phase 3. Of 10 finished, 8 (80%) have results posted.
Among the 11 studies in Diarrhea by Bausch Health Companies Inc., this one is the 9th largest by enrollment, is one of 3 that started in 2005, is one of 8 in phase 3, and was the 7th registered.
Bausch Health Companies Inc.’s Diarrhea studies by the year they started, since 2004.
1 of the studies testing rifaximin in Diarrhea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285785Bausch Health Americas, Inc.Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea | 2027-04-20 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing rifaximin in Diarrhea, from their registry updates:
Among Bausch Health Companies Inc.’s 11 in Diarrhea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
To determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rifaximin
Drug: Rifaximin
Placebo
Drug: Placebo
Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment
The efficacy of 14 days of rifaximin 600 mg once daily (QD) compared with placebo when taken by healthy subjects to prevent travelers' diarrhea (TD) resulting from all causes.
Time frame: 14 days
| Milestone | Treatment Arm 1 | Placebo Arm |
|---|---|---|
| Started | 106 | 104 |
| Completed | 88 | 69 |
| Not completed | 18 | 35 |
The efficacy of 14 days of rifaximin 600 mg once daily (QD) compared with placebo when taken by healthy subjects to prevent travelers' diarrhea (TD) resulting from all causes.
| Participants | Treatment Arm | Placebo Arm |
|---|---|---|
| Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment | 15 | 48 |
Collected over 14 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Arm | — | 0/106 (0%) | 81/106 (76.4%) |
| Placebo | — | 0/104 (0%) | 93/104 (89.4%) |
| Event | Treatment Arm | Placebo |
|---|---|---|
| DiarrheaGastrointestinal disorders | 62/106 | 83/104 |
| Abdominal PainGastrointestinal disorders | 46/106 | 63/104 |
| Defecation UrgencyGastrointestinal disorders | 33/106 | 43/104 |
| FlatulenceGastrointestinal disorders | 27/106 | 29/104 |
| Rectal tenesmusGastrointestinal disorders | 7/106 | 13/104 |
| headacheNervous system disorders | 9/106 | 10/104 |
| VomitingGastrointestinal disorders | 9/106 | 8/104 |
| HematocheziaGastrointestinal disorders | 5/106 | 6/104 |
| PyrexiaGeneral disorders | 6/106 | 6/104 |
| Age, Continuous(years) | Treatment Arm 1 | Placebo Arm | Total |
|---|---|---|---|
| Mean | 23.5 ± 9.15 | 22.9 ± 7.28 | 23.2 ± 8.26 |
| Sex: Female, Male(Participants) | Treatment Arm 1 | Placebo Arm | Total |
|---|---|---|---|
| Female | 66 | 70 | 136 |
| Male | 40 | 34 | 74 |
The record gives a start of Jun 2005, a primary completion of Sep 2005 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2019, 14 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →